Tag Archives: VNDA

Top 10 Gold Stocks To Invest In Right Now

Today, we’re bringing investors the three best silver stocks to buy now as both silver prices and silver stocks continue to outgain the broader markets in 2016.

Before we get into the three best silver stocks to buy now, here’s why the price of silver is soaring in 2016…

Silver has been one of 2016’s best performing assets. The white metal is up 34.9% year to date. Before a recent pullback, silver prices had risen as much as 50% at their 2016 peak.

And silver stocks are boasting much bigger gains…

So far in 2016, the Global X Silver Miners ETF (NYSE Arca: SIL), a fund that tracks gold mining stocks, has soared more than 151%. That’s roughly 25 times the return of the Dow Jones Industrial Average during the same time.

Top 10 Gold Stocks To Invest In Right Now: Vanda Pharmaceuticals Inc.(VNDA)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Another biotechnology player that looks poised to trigger a big breakout trade is Vanda Pharmaceuticals (VNDA), which is focused on the development and commercialization of clinical-stage drug candidates for central nervous system disorders. This stock has been on fire so far in 2013, with shares up a whopping 258%.

    If you take a look at the chart for Vanda Pharmaceuticals, you’ll notice that this stock has recently broke out above some near-term overhead resistance levels at $12.34 to $12.66 a share with solid upside volume. So far, this breakout has held and now shares of VNDA are quickly moving within range of triggering an even bigger breakout trade.

    Traders should now look for long-biased trades in VNDA if it manages to break out above its 52-week high at $13.30 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action 908,467 shares. If that breakout hits soon, then VNDA will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $17 a share.

    Traders can look to buy VNDA off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $12 a share. One could also buy VNDA off strength once it takes out $13.30 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top 10 Gold Stocks To Invest In Right Now: Methanex Corporation(MEOH)

Advisors’ Opinion:

  • [By Jim Robertson]

    Back in February of last year, we suggested Methanex Corporation (MEOH), which ended up providing us with some pretty good gains in a fairly short amount of time, and based on what’s happening with the stock technically right now, it could be another gainer over the next several days to few weeks.

Top 10 Gold Stocks To Invest In Right Now: iShares MSCI Japan (EWJ)

Advisors’ Opinion:

  • [By Stephen Leeb, Founder and Research Chairman, Leeb Group]

    Despite the 30% plus gains they’ve enjoyed this year, the stocks that comprise the iShares MSCI Japan ETF (EWJ) still trade at 14 times depressed earnings.

Top 10 Gold Stocks To Invest In Right Now: Regeneron Pharmaceuticals, Inc.(REGN)

Advisors’ Opinion:

  • [By Johanna Bennett]

    Shares of biotechnology giant Regeneron Pharmaceuticals (REGN) have climbed more than 4% today after Piper Jaffray analyst Ed Tenthoff upgraded the stock from a neutral to an overweight, with a $446 price target.

    The upgrade comes just a few days after the drug maker released soft guidance for 2017 and forecasts called for slowing sales of the eye drug Eylea.

    But Piper Jaffrays Tenthoff argues that anticipated approvals and deep pipeline should drive long-term value. Of particular importance: the atopic dermatitis drug Dupixent (dupilumab).

    We are confident in FDA approval of Dupixent (dupilumab) in moderate-to-severe atopic dermatitis by the March 29th PDUFA date and in Europe in late 2017. The Phase III LIBERTY ASTHMA QUEST study has fully enrolled 1,858 persistent asthma patients to 200mg and 300mg subcu Dupixent q2W. We look for data this year to enable an sBLA submission by YE:17. Regeneron is conducting two Phase III trials in nasal polyps and will initiate Phase III pediatric atopic dermatitis and asthma trials. The company will report data from a Phase II eosinophilic esophagitis study in 1H:17 and begin a Phase II food allergy study in 2H:17. The FDA has deemed Sanofi’s Le Trait facility “acceptable”. As a result, we anticipate the partners will refile on Kevzara (sarilumab) and could gain approval in 2Q:17. These two launches should turn Regeneron’s antibody alliance with Sanofi profitable.

    Todays news is the latest development in what has been a volatile time the drug maker. The shares have fallen sharply over the during the last three months, the result of a patent suit with Amgen (AMGN) over its anti-cholesterol drug Praluent, which a judge had set it wouldnt be able to sell in the U.S. , But last week, a judge granted a stay that would allow Regeneron to sell Praluent. It also fueled a pop in its shares.

    The next day, however, Regeneron reported earnings, and while profits o

  • [By Todd Campbell, Demitrios Kalogeropoulos, and Reuben Gregg Brewer]

    In the case of these three stocks, however, it may be worth taking a gamble. Our contributors think catalysts at Regeneron Pharmaceuticals (NASDAQ:REGN), Royal Dutch Shell (NYSE:RDS-B), and United Parcel Service (NYSE:UPS) can get them back to their winning ways. Read on to find out if these down-and-out stocks are right for your portfolio.

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) tumbled to the bottom of the S&P 500 today after a judge said the company could be forced to stop selling an anti-cholesterol drug due to violating an Amgen (AMGN) patent.

    Agence France-Presse/Getty Images

    Regeneron Pharmaceuticalsdropped 5.8% to $358.68 today, while the S&P 500 rose 0.4% to 2,276.98.

    Chardan’sGbola Amusa takes a victory lap:

    Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.

    While the loss is bad news for Regeneron, Barron’s Johanna Bennettargues that it could herald a comeback for Amgen.

    Regeneron’s market capitalization fell to $38.5 billion today from $40.2 bil

  • [By Chris Lange]

    Shares of Amgen Inc. (NASDAQ: AMGN) saw a handy gain to close out the week after the company won a Delaware court ruling that blocked Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) from selling their cholesterol-lowering drug in the United States. Essentially the court found that the drug Praluent actually infringed upon Amgens patents for its rival treatment Repatha.

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.

  • [By Ben Levisohn]

    It hasn’t been an easy time for investors inRegeneron Pharmaceuticals (REGN) recently…and today’s price action is likely to reinforce the sense of whiplash they must be feeling.

    Agence France-Presse/Getty Images

    What do I mean? Regeneron’s dropped 14% during the last three months, the result of a patent suit with Amgen(AMGN) over its anti-cholesterol drug Praluent, which a judge had set it wouldn’t be able to sell in the U.S.Then last night, there was finally good news: Ajudge ordered a stay, which would allow Regeneron to sell Praluent, and resulted in a 2% pop in its shares last night after the market close. But then Regeneron reported earnings, and while profits of $3.04 cents a share metthe Street consensus, Regeneron missed on sales and offered disappointing guidance. That caused Regeneron shares to sink 2.1% in pre-open trading.

    Fast forward to this afternoon, and and now they’re up nearly 3%. Credit Suisse analyst Alethia Young and team explain why the injunction outweighs the earnings:

    Company issued Eylea guidance for 2017- they guided single digit
    percentage growth over 2016. Consensus had been for 12% growth and we
    had modeled 11% growth.

    EPS for 4Q came in at $3.04 in line with $3.04 consensus. Since the company has already provided OpEx guidance for 2017 and the Eylea 4Q estimate ahead of today we think earnings are less of a focus.

    We are curious where in the single digit percentage growth for Eylea the company means- 9% YoY growth wouldnt be too far from consensus vs. 3%
    growth…

    As we wrote last night, we would expect shares to trade up due to the injunction stay. We would expect shares to be up 2-4% from the injunction stay, but the effect might be muted somewhat by the Eylea guide. We would guess shares might be up 1 to 3% today.

    Shares ofRegeneron Pharmaceuticals have gained 2.8% to $363.04 at 1:57 p.m. today, while the iS

Top 10 Gold Stocks To Invest In Right Now: DAVIDsTEA Inc.(DTEA)

Advisors’ Opinion:

  • [By Monica Gerson]

    DavidsTea Inc (NASDAQ: DTEA) is expected to post its quarterly earnings at $0.43 per share on revenue of $71.74 million.

    SemiLEDs Corporation (NASDAQ: LEDS) is estimated to post its quarterly earnings.

Top 10 Gold Stocks To Invest In Right Now: Home Federal Bancorp Inc.(HOME)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of At Home Group Inc (NYSE: HOME) were down 10 percent to $23.19. At Home Group reported Q2 adjusted earnings of $0.18 per share on revenue of $232.1 million.

  • [By Sofia Horta e Costa]

    Sanofi fell 2.6 percent after withdrawing a U.S. application for a diabetes drug. Cie. Financiere Richemont (CFR) SA dropped 2.3 percent as revenue missed analysts estimates. Vivendi SA advanced 2.7 percent after saying it will begin a formal study to separate its French phone unit from its media businesses. Home Retail Group Plc (HOME) surged 5.4 percent to a two-year high as sales exceeded projections.

Top 10 Gold Stocks To Invest In Right Now: PACCAR Inc.(PCAR)

Advisors’ Opinion:

  • [By Jim Cramer]

    The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Machinery industry. The net income increased by 16.1% when compared to the same quarter one year prior, going from $371.40 million to $431.20 million.

     

  • [By Jim Cramer]

    PACCAR INC has improved earnings per share by 16.3% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, PACCAR INC increased its bottom line by earning $3.82 versus $3.30 in the prior year. This year, the market expects an improvement in earnings ($4.58 versus $3.82).

     

  • [By Jim Cramer]

    The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Machinery industry and the overall market, PACCAR INC’s return on equity exceeds that of both the industry average and the S&P 500.

     

  • [By Laurie Kulikowski]

    We rate PACCAR INC as a Buy with a ratings score of B-. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company’s strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, notable return on equity, attractive valuation levels and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. 

  • [By Jim Cramer]

    Despite the weak revenue results, PCAR has outperformed against the industry average of 21.6%. Since the same quarter one year prior, revenues slightly dropped by 1.6%. The declining revenue has not hurt the company’s bottom line, with increasing earnings per share.

     

  • [By Vikram Nagarkar]

    NVIDIA has also recently announced several partnerships lately, like the one with Microsoft,dubbed Olympus, aimed at maximizing GPU performance for data centers. Then there are also other partnerships in the self-driving cars space, like the one with Bosch, and another one with PACCAR (NASDAQ:PCAR), to develop autonomous trucks. Of course, most of these partnerships will most likely take a while before they can translate to any monetary benefits for NVIDIA. What these deals do, though, is reinforce NVIDIA’s grip over this market, which even pushed Intel (NASDAQ:INTC)to acquire Mobileye (NYSE:MBLY), to build a presence in this space. Mobileye is the company that lost business from Tesla Inc (NASDAQ:TSLA)to NVIDIA last year. Putting that aside, more importantly, the price that Intel is paying to acquire Mobileye has indirectly pointed to the fact that NVIDIA may be significantly undervalued.

Top 10 Gold Stocks To Invest In Right Now: Leading Brands Inc(LBIX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Leading Brands, Inc (USA) (NASDAQ: LBIX) shares were also up, gaining 145 percent to $3.31 on no formal news from company. The stock rallied 215 percent over Tuesday and Wednesday of this week amid trader speculation stock could be sympathy play on move higher in Helios & Matheson. However, Leading Brands shares sold off 27 percent on Thursday.

  • [By Lisa Levin]

    Leading Brands, Inc (USA) (NASDAQ: LBIX) shares dropped 13 percent to $1.99 following Q2 results. Leading Brands posted Q2 EBITDAS of $0.00 per share, compared to $0.09 per share during the same period last year.

  • [By Lisa Levin]

    Leading Brands, Inc (USA) (NASDAQ: LBIX) shares shot up 66 percent to $2.49 following Q1 results. Leading Brands reported Q1 earnings of $0.10 per share on revenue of $3.033 million.

Top 10 Gold Stocks To Invest In Right Now: Arris Group Inc(ARRS)

Advisors’ Opinion:

  • [By Michael A. Robinson]

    Based in San Francisco, Dedrone also has the backing of Dominic Orr, CEO of Aruba Networks, a unit of Hewlett Packard Enterprise Inc. (NYSE: HPE); and Selina Lo, CEO of Ruckus Wireless, a unit of Arris International PLC (Nasdaq: ARRS).

Top 10 Gold Stocks To Invest In Right Now: Live Nation Entertainment, Inc.(LYV)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    For his “Executive Decision” segment, Cramer checked in with Michael Rapino, president and CEO of Live Nation Entertainment (LYV) , a stock that’s up 44% since Cramer last spoke with him a little more than a year ago but also one that fell 3% in today’s session on what appeared to be solid quarterly results.

Hot Gold Stocks To Watch For 2018

Peter Krauth

Gold prices haven’t been making headlines to compete with record-high stocks or Bitcoin reaching $10,000. But that’s all about to change…

The price of gold has appeared stagnant since October.

Normally, traders flock to the precious metal during times of uncertainty and instability. That’s why it was surprising that not even another ballistic missile fired by North Korea was enough to rally gold prices.

Hot Gold Stocks To Watch For 2018: Netease.com Inc.(NTES)

Advisors’ Opinion:

  • [By Sreekanth Anasa]

    Shares of Hangzhou, China-based NetEase Inc (NASDAQ:NTES)popped 14% in the Feb 16th trading session after the company reported stellar Q4 and full-year 2016 earnings on Feb 15th after market close. The Chinese online gaming giant delivered an EPS of $4.30 on revenues of $1.74B beating EPS estimates by $0.86 and revenue estimates by $16oM. NetEase’s revenue grew by an impressive 53.1% YoY for Q4 and 67.7% for the full year 2016. On the back of these strong numbers, NTES stock closed at an all-time high of $298.73 in yesterday’s trading session. NTES stock might have gone up very high too soon. There could be a correction around the corner but still NTES stock is a great long-term proposition with much more upside left. Here’s why.

  • [By Joe Tenebruso]

    Shares ofNetEase (NASDAQ:NTES)popped 20.1% last month, according to data provided byS&P Global Market Intelligence, as the Chinese internet technology company’s strong fourth-quarter earnings report was applauded by investors.

Hot Gold Stocks To Watch For 2018: PVH Corp.(PVH)

Advisors’ Opinion:

  • [By Lisa Levin]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Accenture Plc (NYSE: ACN) to report quarterly earnings at $1.3 per share on revenue of $8.34 billion before the opening bell. Accenture shares gained 0.41 percent to $127.00 in after-hours trading.
    Analysts expect Micron Technology, Inc. (NASDAQ: MU) to post quarterly earnings at $0.85 per share on revenue of $4.64 billion after the closing bell. Micron shares gained 0.88 percent to $26.29 in after-hours trading.
    Five Below Inc (NASDAQ: FIVE) reported better-than-expected earnings for its fourth quarter on Wednesday. Five Below shares climbed 8.23 percent to $41.27 in the after-hours trading session.
    Before the markets open, Conagra Brands Inc (NYSE: CAG) is projected to report its quarterly earnings at $0.44 per share on revenue of $1.98 billion. Conagra shares rose 1.73 percent to $41.18 in after-hours trading.
    PVH Corp (NYSE: PVH) posted upbeat earnings for its fourth quarter and issued a strong earnings forecast. PVH shares surged 7.15 percent to $97.35 in the after-hours trading session.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Seth McNew]

    PVH Corp.(NYSE:PVH)– the parent company of well-known brands like Calvin Klein, Tommy Hilfiger,and Speedo USA — got a positive market reaction today following the release of its Q4 and full-year earnings. Thestock was up as much as 10% during the trading day.

  • [By Ben Levisohn]

    PVH (PVH) slipped to the bottom of the S&P 500 today as consumer discretionary stocks fell.

    Getty Images

    Shares of PVH dropped 5.1% to $102.45 today, while the S&P 500 finished little changed at 2,191.95. The S&P 500 Consumer Discretionary Sector index fell 0.6%

    PVH reported better-than-expected earnings on Nov. 30, but offered disappointing guidance. In a note released on Dec. 1, Wunderlich analyst Eric Bederkept the faith with the stock:

    We are reiterating our Buy rating, $125 price target and FY18 EPS and raising our FY17 EPS to $6.75 (From $6.63) after PVH Corp. (PVH) once again handily beat conservative guidance for 3Q, driven by market share gains in the domestic wholesale business and strong international growth, and provided what we view as conservative guidance for 4Q. We believe the company has continued to make strides in driving solid upside despite material FX and related tourist traffic issues. Further, we believe PVH, with Tommy Hilfiger womens domestic business shifting to a licensed model, should drive further margin upside. We continue to view PVH as a key winner in the apparel segment and believe the company continues to have numerous levers to drive bottom line upside.

    PVH’s market capitalization fell to $8.2 billion today, from $8.7 billion yesterday.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was PVH Corp. (NYSE: PVH) which jumped 8.5% to $98.55. The stocks 52-week range is $82.10 to $115.40. Volume was 4.3 million which is above the daily average of around 1.2 million shares.

Hot Gold Stocks To Watch For 2018: Greenlight Capital Re Ltd.(GLRE)

Advisors’ Opinion:

  • [By Jim Robertson]

    Note that hedge fund mogul David Einhorn has been a director ofthe predecessor company since May 2006. Mr. Einhorn co-founded, and has served as the President of, Greenlight Capital, Inc., since January 1996. Funds managed by Greenlight are some ofthe Companys principal stockholders. Since July 2004, Mr. Einhorn has served as Chairman of the Board of Greenlight Capital Re, Ltd (Nasdaq: GLRE).

Hot Gold Stocks To Watch For 2018: Vanda Pharmaceuticals Inc.(VNDA)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Another biotechnology player that looks poised to trigger a big breakout trade is Vanda Pharmaceuticals (VNDA), which is focused on the development and commercialization of clinical-stage drug candidates for central nervous system disorders. This stock has been on fire so far in 2013, with shares up a whopping 258%.

    If you take a look at the chart for Vanda Pharmaceuticals, you’ll notice that this stock has recently broke out above some near-term overhead resistance levels at $12.34 to $12.66 a share with solid upside volume. So far, this breakout has held and now shares of VNDA are quickly moving within range of triggering an even bigger breakout trade.

    Traders should now look for long-biased trades in VNDA if it manages to break out above its 52-week high at $13.30 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action 908,467 shares. If that breakout hits soon, then VNDA will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $17 a share.

    Traders can look to buy VNDA off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $12 a share. One could also buy VNDA off strength once it takes out $13.30 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Hot Gold Stocks To Watch For 2018: Daimler AG (DDAIF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Last decennium, the popularity of both French Peugeot and Citro毛n has lost traction against that of German car manufacturers. PSA experienced declining sales, while German car manufacturers Volkswagen (OTCPK:VLKAY), BMW (OTCPK:BMWYY) and Daimler (OTCPK:DDAIF) have been stacking up sales records year after year over the last 6 years.

  • [By SEEKINGALPHA.COM]

    Apart from the locals, the global competitors have also made some quick moves to make their presence felt in China. According to Reuters, Volkswagen (OTCPK:VLKAY) has recently signed a preliminary deal to set up a joint venture with China-based Anhui Jianghuai Automobile (JAC) for making electric vehicles. However, the deal has enough hurdles in its path. Also, Daimler (OTCPK:DDAIY) (OTCPK:DDAIF) is also readying some electric cars for China under the Mercedes-Benz brand.

  • [By SEEKINGALPHA.COM]

    Daimler-Mercedes (OTCPK:DDAIF)

    The Wall Street Journal reported that, “Daimler plans to unveil an electric concept car at (next month’s) Paris Auto show. Leaks suggest this will be accompanied by bullish plans to release at least six electric cars”. Of course, Daimler is already quite advanced in EVs with its partnership in China with BYD. As I write this, the Paris Auto show has begun, where “Daimler Mercedes-Benz unveiled a battery-powered sport-utility vehicle, a direct competitor to Tesla’s Model X, which will have a range of 310 miles on a single charge and is slated to launch in 2020. The vehicle will be part of a new sub-brand of Mercedes called EQ”.

  • [By SEEKINGALPHA.COM]

    Companies like Volvo (OTCPK:VOLVY), General Motors (NYSE:GM), Suzuki (OTCPK:SZKMF), Mercedes (OTCPK:DDAIF), and Ford (NYSE:F) are all using the small Swedish company’s tech. The most prominent use for zForce is in the dashboard infotainment center, but it’s also being used as gesture control for closing the tailgate or opening a door and even in using the steering wheel.

  • [By SEEKINGALPHA.COM]

    Through an alliance and investment in Nissan in 1999 Renault currently holds 43% of Japanese car manufacturer Nissan. Since 1999 Nissan has performed well and currently Nissan is worth $43B. Nissan is attractively valued with a P/E of 6.9 a P/B of 0.92 and P/S of 0.41 and a dividend yield of 4.2%. Renault’s stake of 43% in Nissan is worth ($43*0.43=) $18.5B. This means that the other operations of Renault including its 73.3% stake in leading Russian car manufacturer AutoVaz and 1.55% stake in Daimler are valued at only $8.5B. The market value of AutoVaz is $644M which means Renaults stake is worth approximately $472M. Daimler (OTCPK:DDAIF) is worth $77.4B which leads to a value of 1.2B for the 1.55% piece owned by Renault.

  • [By John Rosevear]

    So without further ado, let’s take a closer look at the three: General Motors (NYSE:GM), Daimler AG (NASDAQOTH:DDAIF), and Delphi Automotive (NYSE:DLPH).

Hot Gold Stocks To Watch For 2018: Siebert Financial Corp.(SIEB)

Advisors’ Opinion:

  • [By Cameron Saucier]

    Siebert (Nasdaq: SIEB) is a holding company that has a retail discount brokerage business through its subsidiary, Muriel Siebert & Co. SIEB rose 60% last month after it announced a purchasing agreement with Kennedy Cabot Acquisition. Under the agreement, Kennedy Cabot will purchase shares of SIEB. SIEB is currently trading at $3.37 per share and is up 157% YOY.

  • [By Jim Robertson]

    On Tuesday, our Under the Radar Moversnewsletter suggested shorting small cap discount brokerageSiebert Financial Corp (NASDAQ: SIEB):

    Siebert Financial has been on our watchlist for a while, overbought and toying with the idea of a pullback. We’re finally starting to see evidence that the weight of the gain is taking a toll. We’ve seen a string of lower highs following the last bullish gasp from the 9th. We’re going to assume that was the pivot point. (It has been so far, anyway.)

us stock market hours

In just 12 months, shares of GW Pharmaceuticals (NASDAQ:GWPH) have shot up 125%. Over the past five years, the market cap of the cannabinoid-focused biotech has increased by well over 1,100%. Is GW Pharmaceuticals still a good pick for investors — or is this hot marijuana stock just too expensive to buy right now?

Image source: Getty Images.

Over-hyped?

Some would argue that the prospects for GW Pharmaceuticals are over-hyped. What they really mean is that the prospects for the company’slead cannabinoidcandidate Epidiolex are over-hyped. GW’s fortunes depend on theexperimental drug.

It’s not that many doubt that Epidiolex will win regulatory approval. GW Pharmaceuticals announced results from three different late-stage clinical studies that found Epidiolex helped reduce seizure frequency in patients with Dravet syndrome and Lennox-Gastaut syndrome (LGS), both of which are rare forms of epilepsy.While there’s always a possibility that the U.S. Food and Drug Administration (FDA) could turn down approval of the drug, Epidiolex’s chances appear to be pretty good.

us stock market hours: Vanda Pharmaceuticals Inc.(VNDA)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Another biotechnology player that looks poised to trigger a big breakout trade is Vanda Pharmaceuticals (VNDA), which is focused on the development and commercialization of clinical-stage drug candidates for central nervous system disorders. This stock has been on fire so far in 2013, with shares up a whopping 258%.

    If you take a look at the chart for Vanda Pharmaceuticals, you’ll notice that this stock has recently broke out above some near-term overhead resistance levels at $12.34 to $12.66 a share with solid upside volume. So far, this breakout has held and now shares of VNDA are quickly moving within range of triggering an even bigger breakout trade.

    Traders should now look for long-biased trades in VNDA if it manages to break out above its 52-week high at $13.30 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action 908,467 shares. If that breakout hits soon, then VNDA will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $17 a share.

    Traders can look to buy VNDA off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $12 a share. One could also buy VNDA off strength once it takes out $13.30 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

us stock market hours: QC Holdings Inc.(QCCO)

Advisors’ Opinion:

  • [By Monica Gerson]

    QC Holdings (NASDAQ: QCCO) shares tumbled 2.58% to reach a new 52-week low of $2.27. QC Holdings’ trailing-twelve-month profit margin is 0.60%.

    NewLead Holdings (NASDAQ: NEWL) shares dipped 6.56% to touch a new 52-week low of $0.08 after the company completed the acquisition of titles in the Viking Mine located in Kentucky, USA.

us stock market hours: Cyclacel Pharmaceuticals Inc.(CYCC)

Advisors’ Opinion:

  • [By Alex McGuire]

    As a service to our readers, the following list provides the 10 top pharmaceutical stocks to watch this month (May 2017), including the biggest gainers from April…

    Pharmaceutical Stock Current Share Price April 2017 Gain
    Cleveland BioLabs Inc. (Nasdaq: CBLI) $3.62 +120.6%
    Nexvet Biopharma Plc. (Nasdaq: NVET) $6.61 +69.7%
    Motif Bio Plc. (Nasdaq ADR: MTFB) $10.10 +68.2%
    Axovant Sciences Ltd. (NYSE: AXON) $24.43 +62.3%
    Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) $5.49 +46.7%
    Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) $8.67 +44.9%
    Akebia Therapeutics Inc. (Nasdaq: AKBA) $13.07 +43.3%
    Akorn Inc. (Nasdaq: AKRX) $33.28 +38.9%
    Rockwell Medical Inc. (Nasdaq: RMTI) $8.78 +37.4%
    Akari Therapeutics Plc. (Nasdaq ADR: AKTX) $15.02 +35.4%

    The best-performing pharma stock of the month – Cleveland BioLabs Inc. – surged 120.6% to $3.53 a share by April 28. That crushed both the Nasdaq Biotech Index’s 1.5% gain and the Dow Jones’ 1.3% rise over the same period.

  • [By Alex McGuire]

    These are the 10 best penny stocks that have seen the biggest returns over the last week (March 7 – March 14)…

    Penny StockCurrent PriceWeekly Gain (March 7 – March 14)Ocera Therapeutics Inc. (Nasdaq: OCRX)$1.47+147.1%Internap Corp. (Nasdaq: INAP)$3.28+41.4%Soligenix Inc. (Nasdaq: SNGX)$2.94+40%Navios Maritime Partners LP (NYSE: NMM)$2.63+37%QuickLogic Corp. (Nasdaq: QUIK)$2.14+30.5%Adamis Pharmaceuticals Corp. (Nasdaq: ADMP)$4.60+22.7EXCO Resources Inc. (NYSE: XCO)$0.65+20.5%Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC)$4.38+20.3%Hebron Technology Co. Ltd. (Nasdaq: HEBT)$3.99+19.1%Curis Inc. (Nasdaq: CRIS)$2.85+18.4%

    As a reminder, this is only a tracking metric of penny stocks trading on SEC-regulated exchanges like the Nasdaq and NYSE. Although these top penny stocks are safer than those trading on the pink sheets, we don’t recommend buying any of them without the proper amount of financial research.

us stock market hours: MDU Resources Group, Inc.(MDU)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Monday, utilities shares fell by 1.08 percent. Meanwhile, top losers in the sector included South Jersey Industries Inc (NYSE: SJI), down 4 percent, and MDU Resources Group Inc (NYSE: MDU), down 4 percent.

us stock market hours: New York REIT, Inc.(NYRT)

Advisors’ Opinion:

  • [By Paul Ausick]

    New York REIT Inc. (NYSE: NYRT) dropped about 11.8% Thursday to post a new 52-week low of $8.55 after closing at $9.69 on Wednesday. The stock’s 52-week high is $10.15. Volume was nearly 20 times the daily average of around 1.9 million shares. The company, which is in the process of liquidating its assets in New York City, announced quarterly results Wednesday afternoon, including a liquidation value of the portfolio of $9.25 per share.

  • [By Paul Ausick]

    New York REIT Inc. (NYSE: NYRT) dropped about 2.9% Wednesday to post a new 52-week low of $8.01after closing Tuesday at $8.25. The 52-week high is $10.15. Volume of around 4.7 million shares traded was more than triple the daily average. The company had no specific news.

us stock market hours: Fiat Chrysler Automobiles N.V.(FCAM)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    The showstopper by far in the early going is Waymo’s self-driving minivan (pictured below) in partnership with Fiat Chrysler (FCAM) . Waymo’s ultimate mom-mobile, coming from a business that was spun-off from Google’s parent company Alphabet Inc. (GOOG) last month, is equipped with self-driving sensors and vision systems.

day trading penny stocks

5 Ways Washington Is Choking Your Annuity Business

3 Reasons DOL Fiduciary Rule Will Stay Intact: ERISA Attorney Wagner

Victor Fetter Is Out at LPL; Former AmEx, eBay Exec Is In

Most advisors agree client anxiety — often caused by politics — led to poor investment decisions last year, according to new data released by Hartford Funds

Of the 218 advisors surveyed, 62% said anxiety hurt investor decision-making over the last 12 months.

The “Contrarian’s Contrarian” tells ThinkAdvisor why the economy is headed for demographic-fueled disaster and shares dark predictions for Trump presidency.

You are signed up!

ThinkAdvisor’s TechCenter is an educational resource designed to give you a competitive edge by keeping you abreast of new tech innovations and need-to-know information that can be applied to your business. Financial Education Resource Center

ThinkAdvisor and the College for Financial Planning have partnered to bring you a series of helpful educational tools that you can use to take your career to the next level. Resources Millennials: Successfully Tapping into the Future of Your Practice

Millennials are the future of your practice; both as clients and employees. Understand how they think to capture them as clients, attract them as employees…

day trading penny stocks: BioAmber Inc.(BIOA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Bioamber Inc (NYSE: BIOA) shares dropped 19 percent to $2.55. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.

  • [By Paul Ausick]

    BioAmber Inc. (NYSE: BIOA) dropped nearly 29% Friday to post a new 52-week low of $2.24 after closing Thursday at $3.14. Volume of more than 1.5 million shares was about 6 times the daily average of around 240,000. The company’s annual report, filed on Thursday with its quarterly results, included a “going concern” statement from the company’s independent auditing firm.

  • [By Markus Aarnio]

    BioAmber (BIOA) is a sustainable chemicals company. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in a wide variety of everyday products including plastics, resins, food additives and personal care products.

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
    Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
    The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
    Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
    Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
    Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
    AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
    Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli

day trading penny stocks: Dominion Resources, Inc.(D)

Advisors’ Opinion:

  • [By Jim Jubak, Senior Markets Editor, MoneyShow.com]

    A big part of that is Wednesday’s news that the US Department of Energy had approved a permit for Dominion Resources (D) to export liquefied natural gas from an existing liquefied natural gas import terminal in Maryland.

  • [By David Dittman]

    But power generators across the country, including Dominion Resources Inc (NYSE: D) in Virginia and Southern Company (NYSE: SO) in the Southeast, are taking significant steps to boost their solar capacity.

  • [By Justin Loiseau]

    Dominion (NYSE: D  ) added its name to the short list of U.S. companies approved to export LNG to non-Free Trade Agreement countries around the world. Its $3.6 billion Cove Point plant in Maryland will flip the facility’s focus on its head from imports from across the globe, to exports to India and Japan.

  • [By Ben Levisohn]

    Iron Mountain has gained 2.6% to $26.55 at 3:05 p.m., making it the fourth-best performer in the S&P 500, ahead of WPX Energy (WPX), which has gained 2.4% to $19.94, Pinnacle West Capital (PNW), which has gained 2.3% to $53.55 and Dominion Resources (D), which has risen 2.1% to $59.85.

  • [By Shauna O’Brien]

    JP Morgan reported on Friday that it has raised its rating on energy producer Dominion Resources, Inc. (D).

    The firm has upgraded D from “Neutal” to “Overweight,” and has given the company a $68 price target. This price target suggests a 12% increase from Thursday’s closing price of $59.78.

    Analysts see midstream growth and its MLP formation adding value to existing assets.

    Dominion Resources shares were up $1.02, or 1.71%, during pre-market trading Friday. The stock is up 15% YTD.

day trading penny stocks: Golden Star Resources Ltd(GSS)

Advisors’ Opinion:

  • [By Cameron Saucier]

    Golden Star (NYSEMKT: GSS) is a gold mining and exploration company, and operates gold mines in Ghana, West Africa. GSS is up 396% YTD after it announced in July that it had begun pre-commercial production of gold in an underground mine in Ghana. GSS is trading at $0.825 per share on Monday intraday.

day trading penny stocks: Vanda Pharmaceuticals Inc.(VNDA)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Another biotechnology player that looks poised to trigger a big breakout trade is Vanda Pharmaceuticals (VNDA), which is focused on the development and commercialization of clinical-stage drug candidates for central nervous system disorders. This stock has been on fire so far in 2013, with shares up a whopping 258%.

    If you take a look at the chart for Vanda Pharmaceuticals, you’ll notice that this stock has recently broke out above some near-term overhead resistance levels at $12.34 to $12.66 a share with solid upside volume. So far, this breakout has held and now shares of VNDA are quickly moving within range of triggering an even bigger breakout trade.

    Traders should now look for long-biased trades in VNDA if it manages to break out above its 52-week high at $13.30 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action 908,467 shares. If that breakout hits soon, then VNDA will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $17 a share.

    Traders can look to buy VNDA off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $12 a share. One could also buy VNDA off strength once it takes out $13.30 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

day trading penny stocks: IDT Corporation(IDT)

Advisors’ Opinion:

  • [By Lisa Levin]

    IDT Corporation (NYSE: IDT) was down, falling around 15 percent to $15.88 following Q2 results. IDT reported fiscal second-quarter earnings of $875,000.

Top 10 Heal Care Stocks To Watch For 2018

House Ways and Means Committee Chairman Rep. Kevin Brady (R-TX) has proposed eliminating the federal adoption tax credit. (Photo by Alex Wong/Getty Images)

I normally would follow a headline like the one above with something humorous. Not this time: There’s nothing funny about this.

Catherine Rampell of The Washington Post pointed out in a spectacular column on Friday that the Trump administration and congressional Republicans want to implement totally contradictory policies when it comes to the working poor and middle class having sex.

That’s right: Contrary to their protests that they want the federal government nowhere near it, the GOP is looking directly into your bedroom.

Rampell notes that, on the one hand, the press release sent to Congress by President Trump’s Office of Management and Budget (It wasn’t a “budget;” please don’t call it that.) last Thursday includes eliminating federal support for Planned Parenthood. That will increase the number of children who are born and should also increase the number of children put up for adoption.

Top 10 Heal Care Stocks To Watch For 2018: Gerdau S.A.(GGB)

Advisors’ Opinion:

  • [By Manikandan Raman]

    On the news, Freeport-McMoRan surged 12 percent to $10.20 and Lundin Mining climbed 12 percent to $3.33. Gerdau SA (ADR) (NYSE: GGB) rose 19 percent to $1.23, Vale SA (ADR) (NYSE: VALE) advanced 18 percent to $4.85 and Banco Bradesco SA (ADR) (NYSE: BBD) gained 11 percent to $7.15.

Top 10 Heal Care Stocks To Watch For 2018: SORL Auto Parts Inc.(SORL)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
    Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
    Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
    Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
    TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
    Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
    Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
    Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
    Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
    Sorl Auto
  • [By Monica Gerson]

    Sorl Auto Parts, Inc. (NASDAQ: SORL) is expected to post its quarterly earnings at $0.20 per share on revenue of $55.35 million.

    Clean Diesel Technologies, Inc. (NASDAQ: CDTI) is projected to post a quarterly loss at $0.18 per share on revenue of $10.25 million.

  • [By Lisa Levin]

    Sorl Auto Parts, Inc. (NASDAQ: SORL) shares were also up, gaining 33 percent to $6.02 after the company reported strong Q1 results and raised its FY17 sales guidance.

Top 10 Heal Care Stocks To Watch For 2018: Barnes & Noble, Inc.(BKS)

Advisors’ Opinion:

  • [By Peter Graham]

    University book store operatorBarnes & Noble Education Inc (NYSE: BNED), a spinoff fromBarnes & Noble, Inc (NYSE: BKS), reported Q1 2018 earnings before the market opened Wednesday with shares now down more than 18%. Consolidated sales increased $116.5 million or 48.7%to $355.7 million primarily due to the MBS acquisition. BNC opened 24 new physical stores with estimated annual sales of $49 million, bringing total stores operated by BNC to 781 locations as of July 29, 2017. MBS opened 10 new virtual stores this quarter with estimated annual revenue of $4 million, bringing total contracts operated by MBS to 714 as of July 29, 2017. Comparable store sales decreased 2.5%representing approximately $5.5 million in revenue versus 2.8% for BNC in the prior year quarter. The decrease is primarily attributable to textbook sales, which were down 8.5% partially offset by an increase in general merchandise sales of 3.3%. The consolidated net loss was $34.8 million versus anet loss of $27.9 million. Outlook was given as follows:

  • [By Peter Graham]

    A long term performance chart shows Chegg Inc finallymovingabove IPO levels while potential performance benchmarks such as Houghton Mifflin Harcourt Co (NASDAQ: HMHC) and Barnes & Noble Education Inc (NYSE: BNED), a spin off from Barnes & Noble, Inc (NYSE: BKS), have seen their performance slip:

  • [By Paul Ausick]

    Bookseller Barnes & Noble Inc. (NYSE: BKS) posted its highest-ever stock price at above $45 a share in March of 2006. By March of 2011 it had dropped below $9 a share, and it posted a new all-time low of $7.25 in February of last year.

Top 10 Heal Care Stocks To Watch For 2018: Coca-Cola Company (The)(KO)

Advisors’ Opinion:

  • [By Javier Hasse]

    “I can see Isodiol being the dominant company in the CBD space, not only in the U.S., but in the whole world,” Washington said, pointing out that he believes the firm will soon be able to compete with early-entrant GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), even becoming the The Coca-Cola Co (NYSE: KO) or PepsiCo, Inc. (NYSE: PEP) of cannabis therapeutics.

  • [By Money Morning Staff Reports]

    Represented are Wells Fargo & Co. (NYSE: WFC), Coca-Cola Co. (NYSE: KO), and Kraft Heinz Co. (Nasdaq: KHC), just to name a few.

    The Berkshire portfolio has 34 dividend stocks in total; of those, eight yield dividend returns in excess of 3% annually, according to Buffett’s latest SEC 13F filing on Feb. 14, 2017.

  • [By Ben Levisohn]

    So we find ourselves in the position we have for most of this year: positive on the market averages but less confident in what stocks to buy. While banks have clearly been the flavor of the day we have generally avoided those names. Both Citigroup (C) and Bank of America (BAC) are only now hitting six year highs and we have never advocated chasing winners. Meanwhile the staid, safe defensive stocks (value) like P&G (PG), Coke (KO), and Philip Morris (PM) are lagging. The dichotomy might be illustrated by retailers where Best Buy has been roaring while Gap Stores has been tanking…

  • [By Demitrios Kalogeropoulos]

    That’s why many investors shop among the short list ofDividend Aristocrats, which are companies that boast an unbroken streak of at least 25 years of consecutive payout raises. A few members of that elite group have fallen out of favor recently and could represent solid long-term buys. Below, we’ll look at the prospects for market-beating returns fromCoca-Cola(NYSE:KO),Target(NYSE:TGT), andLowe’s(NYSE:LOW).

  • [By Shanthi Rexaline]

    See also: 3 Reasons Alcoa Is No Longer The Curtain-Raising Event Of Earnings Season

    5. DuPont
    Company: E I Du Pont De Nemours And Co (NYSE: DD). Date of Reporting: Tuesday, before the market open. EPS Estimate vs. Year-ago EPS: $1.29 versus $1.24. Revenue Estimate: $7.29 billion versus $7.06 billion. Stock Gain/Loss (year to date): 14.97 percent.
    6. AT&T
    Company: AT&T Inc (NYSE: T). Date of Reporting: Tuesday, after the market close. EPS Estimate vs. Year-ago EPS: $0.74 versus $0.72. Revenue Estimate: $39.82 billion versus $40.52 billion. Stock Gain/Loss (year to date): (-14.6 percent).
    7. Coca-Cola
    Company: The Coca-Cola Co (NYSE: KO). Date of Reporting: Wednesday, before the market open. EPS Estimate vs. Year-ago EPS: $0.58 versus $0.60. Revenue Estimate: $9.65 billion versus $11.52 billion. Stock Gain/Loss (year to date): 8.32 percent.
    8. Boeing
    Company: Boeing Co (NYSE: BA). Date of Reporting: Wednesday, before the market open. EPS Estimate vs. Year-ago EPS: $2.31 versus $2.47. Revenue Estimate: $23.07 billion versus $24.75 billion. Stock Gain/Loss (year to date): 36.03 percent.
    9. Procter & Gamble
    Company: Procter & Gamble Co (NYSE: PG). Date of Reporting: Thursday, before the market open. EPS Estimate vs. Year-ago EPS: $0.78 versus $0.79. Revenue Estimate: $16.02 billion versus $16.1 billion. Stock Gain/Loss (year to date): 4.98 percent.
    10. Verizon
    Company

Top 10 Heal Care Stocks To Watch For 2018: Berkshire Hathaway Inc.(BRK.A)

Advisors’ Opinion:

  • [By Yasin Ebrahim]
     

    Berkshire Hathaway Inc. (NYSE:BRK.A) is an American conglomerate with investments in a variety of businesses from American Express to Coca-Cola. It reported Q3 earnings last week, which were in line with analysts’ expectations, as the group revealed a 7% increase in operating profit compared to the same period last year.

  • [By WWW.THESTREET.COM]

    Warren Buffett’s Berkshire Hathaway (BRK.A) (BRK.B) was upgraded to a “stable” rating outlook at S&P (SPGI) from a “watch negative” outlook on Tuesday.

  • [By Diane Alter]

    The sector took off in November when 13F filings revealed Warren Buffett’s Berkshire Hathaway Inc. (NYSE: BRK.A) bought shares in American Airlines Group Inc. (Nasdaq: AAL), United Continental Holdings Inc. (NYSE: UAL), Southwest Airlines Co. (NYSE: LUV), and Delta.

  • [By WWW.THESTREET.COM]

    While self-driving cars tend to get a lot of press with consumers, Buffett said in May that significant growth of autonomous trucks in particular could cut into the market for rail transporter Burlington Northern, which Buffett’s Berkshire Hathaway  (BRK.A) owns.

  • [By Virendra Singh Chauhan]

    Yes, Warren Buffett has been buying shares of Apple rapidly. In fact, the Buffett-ledBerkshire Hathaway (NYSE:BRK.A) has lapped up over 70M Apple shares between December 31, and Apple’s latest earnings report at the end of January. That’s more than twice the number of shares the company reported in its 13F filing for the period ending December 31. By Warren Buffett’s own admission on CNBC’s ‘Squawk Box’Berkshire Hathaway now has 133M shares of Apple Inc., which equates to $18.5B worth of Apple stock at the last closing price. In other words, Berkshire Hathaway now holds nearly 2.5% of Apple’s total market cap. And well, Warren Buffett has himself bought 123M of those shares. Quoting the Oracle from the ‘Ask Warren’ show, “One of them had had 10 million shares, and then I bought another 123 million shares, or something like that.” The ‘One of them’ here refers to one of Warren’s deputies,Ted Weschler or Todd Combs. When asked why is he buying Apple shares? The Oracle of Omaha remarked: ‘Cause I Liked It.’ Coming to the big question of ‘Why does Warren Buffett now like Apple, the tech giant, after having avoided technology companies for so many years?’

Top 10 Heal Care Stocks To Watch For 2018: Alexion Pharmaceuticals, Inc.(ALXN)

Advisors’ Opinion:

  • [By Johanna Bennett]

    Alexion Pharmaceuticals (ALXN), a drug maker focused on rare diseases, ended Thursday at the top of the list of the best performing stocks in the S&P 500 index.

    The shares climbed almost 3.3%, or $3.78, to close at $118.35, compared to the S&P 500, which fell almost 16 points, or 0.7% to end at 2,328.95.

    Its been a rough two years for Alexion. Since mid-2015, when the stock traded above $200, shares have tumbled on worries about the durability of its main drug Soliris, political furor over high drug prices, and the abrupt departure of two top executives amid an investigation into sales practices.

    The shares are down more than 3% since the start of 2017.

    Solaris sales will be a focus next week when Alexion reports first quarter financial results. Earlier today, Barclays reiterated an overweight rating on the stock and a $115 price target, but raised its 2018 and 2019 earnings estimates, arguing that rivals are unlikely to significantly challenge either Solaris or the experimental drug ALXN1210.

    …we are increasingly comfortable with the Soliris outlook and now forecast 2021E sales at $4.8B vs. our previous $4.6B, which is +5% ahead of consensus. Weve raised 2017 and 2018 adjusted EPS estimates by $0.05 and $0.10 respectively. Our 5-year revenue CAGR increases by +70 bps to 14.7% while EPS growth has improved by +100 bps to 20.0%, near the top of the peer group.

    Barrons weighed in on Alexion in February, which has been bandied about as a takeout candidate. We have argues

    Earlier this week, Credit Suisse analysts listed Alexion as one of three biotech stocks that will steal the spotlight during earnings season.

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) soared to the top of the S&P 500 today after its audit committee found no need to restate the company’s financials.

    Agence France-Presse/Getty Images

    Alexion Pharmaceuticalsgained 9.5% to $139.18 today, while the S&P 500 dipped 0.1% to 2,269.00.

    Morgan Stanley’sMatthew Harrison and team argue that the audit committees report is “lifting a cloud” over Alexion, but they still have their concerns:

    Without significant fireworks mgt. has filed the 10-Q lifting a cloud around the details on the potential wrong doing and its impact. While the “pull-in” sales had less than a 1% impact and do not appear pervasive in use as evidenced by the limited amount outside of 4Q15, we do wonder how the increased scrutiny will impact the selling organization and the potential increased conservatism among personnel going forward. We look forward to 2017 guidance and updates to MG filing and 1210 enrollment at the 4Q16 call.

    Alexion’s market capitalization rose to $31.2 billion today from $28.5 billion yesterday. It reported net income of $144 million on sales of $2.5 billion in 2015.

  • [By Ben Levisohn]

    Three biotech stocks–Alexion Pharmaceuticals (ALXN), Amgen (AMGN), and Celgene (CELG)–reported earnings since yesterday’s close. But just one has seen its shares head higher after the announcement.

    Getty Images

    That would be Alexion, which reported a profit of $1.38, beating forecasts for $1.23, according to Reuters, on sales of $870 million, ahead of analyst expectations for $826.6 million. Those results have sent Alexion shares up 5.1% to $126.87 at 34:35 p.m. today.

    Unfortunately, Amgen and Celgene are trading lower, despite beating earnings forecasts. Credit Suisse analystAlethia Young and team call Amgen’s quarter “mixed,” which helps explain why its stock has dropped 1.4% to $162.25. They explain:

    Product revenues were light by $200M although the company raised their bottom line EPS guidance for 2017. Newer product volume growth seemed sound although some legacy products experienced challenges: Reported revenues were $5.46B vs. consensus of $5.57B. EPS beat with $3.15/sh non-GAAP EPS vs. consensus of $3.00/sh driven by lower OpEx spend, specifically with non-GAAP R&D coming in at $748M vs. $900M consensus. We think results for the quarter were mixed, with some notable headwinds on the topline. After listening to the call, it seems the quarter consisted of various one-type dynamics for products where revenues were light (Enbrel and Repatha). Enbrel missed by close to $200M ($1,181M vs. $1,360M consensus) and we think rheumatology/dermatology dynamics (both pricing and volume) remain a focus for investors. Repatha came in at $50M vs. $72M consensus although the company noted last quarter was helped by a one-time bulk order. Neulasta helped on the topline at $1,210M vs. $1,142M consensus although this was helped by some purchases from larger end customers.

    …while Evercore ISI’s Umer Raffat explains why investors were disappointed by Celgene’s earnings beat:

    Celg

  • [By Paul Ausick]

    Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) posted a new 52-week low of $102.47 on Tuesday, down more than 11% compared with Monday’s closing price of $115.42. The stock’s 52-week high is $157.02. Volume totaled more than 16 million shares, nearly 6 times the daily average of about 3 million. The company announced several executive changes this morning.

  • [By David Sterman]

    Growth-oriented investors should also check out Alexion Pharmaceuticals (Nasdaq: ALXN(link is external)), which falls through the cracks between the massive well-established biotechs, and the small-cap biotechs that are still pre-revenue.

    Alexion targets rare and severe diseases, and has built a broad platform of drugs to treat them. Sales growth has never been less than 37% at any point in the past eight years, and 20% to 25% growth appears locked in over coming years as well. Analysts at UBS, who see 30% upside to their $202 price target, believe that a healthy drug pipeline provides multiple catalysts this year in the form of clinical trial updates. They suggest that shares would be worth $230 in a buyout scenario. 

  • [By Lisa Levin] Related Chardan Analyst Suggests An AveXis-Ionis Pair Trade Why The Biogen-Ionis News Is A Boon For AveXis AveXis' (AVXS) CEO Sean Nolan on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related CLBS Earnings Scheduled For March 17, 2017 15 Biggest Mid-Day Gainers For Thursday Caladrius Biosciences beats by $0.07, beats on revenue (Seeking Alpha) Gainers
    Caladrius Biosciences Inc (NASDAQ: CLBS) shares rose 20.2 percent to $6.13 in pre-market trading after the company reported a narrower-than-expected quarterly loss.
    Arbutus Biopharma Corp (NASDAQ: ABUS) rose 12.3 percent to $3.20 in pre-market trading after the company disclosed that it has licensed LNP delivery technology to Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) for use in single messenger RNA product candidate.
    AveXis Inc (NASDAQ: AVXS) rose 12.2 percent to $81.66 in pre-market trading after the company reported topline data from Phase 1 trial of AVXS-101.
    TOP SHIPS Inc (NASDAQ: TOPS) shares rose 10.5 percent to $2.43 in pre-market trading after surging 109.52 percent on Thursday.
    ChipMOS TECHNOLOGIES INC. (NASDAQ: IMOS) rose 9.8 percent to $17.45 in pre-market trading after declining 0.44 percent on Thursday.
    Sino-Global Shipping America, Ltd. (NASDAQ: SINO) rose 8.3 percent to $3.38 in pre-market trading after climbing 23.81 percent on Thursday.
    Diana Containerships Inc (NASDAQ: DCIX) rose 7.6 percent to $2.99 in pre-market trading after surging 12.55 percent on Thursday.
    Steel Dynamics, Inc. (NASDAQ: STLD) rose 5.2 percent to $37.25 in pre-market trading. Steel Dynamics expects Q1 earnings of $0.77 to $0.81 per diluted share. The company also declared a quarterly cash dividend of $0.1550 per common share.
    Adobe Systems Incorporated (NASDAQ: ADBE)

Top 10 Heal Care Stocks To Watch For 2018: Neo Lithium Corp. (NTTHF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    ILC reminds me of Critical Elements [TSXV:CRE] (OTCQX:CRECF) having five projects (CRE has 11), and also of Galaxy Resources (ASX:GXY) (OTCPK:GALXF) by being diversified across brine and spodumene and across three continents. Also some similarity with Neo Lithium’s (OTC:NTTHF) [TSXV:NLC] early stage Argentinean brine project which I recently wrote about here. However, ILC trades at a much smaller market cap of US$8m to that of Critical Elements (US$85m) or Galaxy Resources (US$724m). This is partly due to ILC giving away significant percentages of their projects, and because they are still in the early stages of development.

Top 10 Heal Care Stocks To Watch For 2018: Vanda Pharmaceuticals Inc.(VNDA)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Another biotechnology player that looks poised to trigger a big breakout trade is Vanda Pharmaceuticals (VNDA), which is focused on the development and commercialization of clinical-stage drug candidates for central nervous system disorders. This stock has been on fire so far in 2013, with shares up a whopping 258%.

    If you take a look at the chart for Vanda Pharmaceuticals, you’ll notice that this stock has recently broke out above some near-term overhead resistance levels at $12.34 to $12.66 a share with solid upside volume. So far, this breakout has held and now shares of VNDA are quickly moving within range of triggering an even bigger breakout trade.

    Traders should now look for long-biased trades in VNDA if it manages to break out above its 52-week high at $13.30 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action 908,467 shares. If that breakout hits soon, then VNDA will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $17 a share.

    Traders can look to buy VNDA off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $12 a share. One could also buy VNDA off strength once it takes out $13.30 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top 10 Heal Care Stocks To Watch For 2018: Profire Energy, Inc.(PFIE)

Advisors’ Opinion:

  • [By Monica Gerson]

    Profire Energy, Inc. (NASDAQ: PFIE) is estimated to post its quarterly earnings at $0.00 per share on revenue of $6.74 million.

    Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

Top 10 Heal Care Stocks To Watch For 2018: Alexandria Real Estate Equities, Inc.(ARE)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Take Alexandria Real Estate Equities (ARE), for example. The company deals heavily in tech real estate in New York and San Francisco among other places.